Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study
Autor: | Nicola Cascavilla, Felicina Li Gioi, Giuseppina Ricciuti, Maurizio Musso, Alessandra Crescimanno, Ferdinando Porretto, Gaetano De Santis, Emilio Iannitto, Annalisa Chiarenza, Ugo Consoli, Attilio Guarini, Maria Cristina Pirosa, Antonino Greco, Giuseppe Tarantini, Marilena Salerno, Saverio Mantuano, Carla Minoia, Donato Mannina, Francesco Di Raimondo, Alessandra Romano, Potito Rosario Scalzulli, Enzo Pavone, Renato Scalone, Anastasia Laura Caruso, Vincenza Bonanno |
---|---|
Rok vydání: | 2020 |
Předmět: |
Bendamustine
Adult Male medicine.medical_specialty Adolescent lymphoma Drug resistance Neutropenia Gastroenterology bendamustine hydrochloride brentuximab vedotin drug resistance Hodgkin disease recurrence 03 medical and health sciences Young Adult 0302 clinical medicine Refractory Recurrence Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Bendamustine Hydrochloride Humans Brentuximab vedotin Aged Brentuximab Vedotin business.industry Hematopoietic Stem Cell Transplantation Hematology General Medicine Middle Aged medicine.disease Prognosis Combined Modality Therapy Hodgkin Disease Lymphoma Regimen Treatment Outcome Drug Resistance Neoplasm 030220 oncology & carcinogenesis Positron-Emission Tomography Toxicity Female business 030215 immunology medicine.drug |
Zdroj: | European journal of haematologyREFERENCES. 104(6) |
ISSN: | 1600-0609 |
Popis: | Objective and methods In order to assess the efficacy of brentuximab vedotin (Bv) in combination with bendamustine (B) in multiple relapsed or refractory (RR) classic Hodgkin lymphoma (cHL), medical records of 47 patients treated with BvB in second relapse or beyond were reviewed. Results The median number of previous treatments was 2 (1-4). Bv was given at 1.8 mg/kg on day 1 and bendamustine at 90 mg/m2 on days 1 and 2 of a 21-day cycle. The median number of BvB cycles was 4 (2-7), and all patients were evaluable for efficacy. The CR and OR rates were 49% and 79%, respectively; 67% of responding patients and 2 in stable disease proceeded to a SCT procedure. After a median follow-up of 19 months (5-47), median PFS was 18 months (95%CI: 23-29), and the 2-year OS was 72%. Significantly longer PFS and OS were observed in patients attaining a major clinical response to treatment and in those who received consolidation with SCT. Fifteen (32%) patients experienced severe (G > 2) toxicity. The main toxicities were neutropenia (23%), gastrointestinal (10%), peripheral sensory neuropathy (11%), and infection (4%). Conclusion Our real-world results suggest that BvB is an effective third-line rescue and bridge-to-transplant regimen for RR-cHL patients. |
Databáze: | OpenAIRE |
Externí odkaz: |